Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in Recurrent or Metastatic Adrenocortical Carcinoma
NCT04318730Phase 2
Key facts
- Status
- Recruiting
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Countries
- 1
- Sponsor
- West China Hospital of Sichuan University
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Conditions
- adrenocortical carcinoma (ACC)
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in adrenocortical carcinoma (ACC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate up to 60 months. Started Oct 2020; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Camrelizumab + Apatinib
Camrelizumab 200mg iv every 3 weeks combined with Apatinib 250 mg p.o. daily.
03
Who it enrols
Adult patients with histologically confirmed metastatic or inoperable adrenocortical carcinoma who have progressed after first-line standard treatment (mitotane or chemotherapy). Patients must have ECOG 0-1 and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Beyond the preview
Go deeper on NCT04318730.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318730.